Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $62.00 Consensus PT from Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have been given an average recommendation of “Buy” by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $61.38.

A number of research firms have commented on CRBP. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price (down from $80.00) on shares of Corbus Pharmaceuticals in a research note on Monday. Piper Sandler initiated coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Vestcor Inc purchased a new position in shares of Corbus Pharmaceuticals during the 3rd quarter valued at approximately $64,000. JPMorgan Chase & Co. increased its holdings in Corbus Pharmaceuticals by 27.0% in the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,172 shares in the last quarter. MetLife Investment Management LLC acquired a new position in shares of Corbus Pharmaceuticals in the third quarter worth about $123,000. Avanza Fonder AB purchased a new stake in shares of Corbus Pharmaceuticals during the 4th quarter worth about $84,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 3rd quarter valued at about $151,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Trading Down 10.2 %

Shares of CRBP opened at $8.78 on Friday. The firm has a market cap of $106.94 million, a PE ratio of -1.87 and a beta of 2.63. Corbus Pharmaceuticals has a 12 month low of $8.74 and a 12 month high of $61.90. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $26.68.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.